Clearpoint Neuro (CLPT) Q1 2025 earnings summary

Executive summary

• Entered a new growth phase focused on cell and gene therapy leadership, workflow efficiency, and global expansion, supporting over 60 biopharma partners as of March 31, 2025.

• Achieved record quarterly revenue of $8.5 million, up 11% year-over-year for Q1 2025, driven by strong growth in single-use navigation and therapy products.

• Launched new products and software, including ClearPoint 3.0 Navigation Software, to increase hospital throughput and address demand for restorative therapies.

• Secured foundational funding through a mix of debt and equity, including a long-term credit facility and equity investment, ensuring multi-year strategic execution.

• Reported an accumulated deficit of $197.4 million as of March 31, 2025, with continued investment in R&D and commercialization.

Financial highlights

• Q1 2025 revenue was $8.5M, up 11% year-over-year from $7.6M in Q1 2024.

• Gross margin improved to 60% from 59% in Q1 2024, with gross profit at $5.1M.

• Net loss for Q1 2025 was $6.0M (EPS: -$0.22), compared to $4.1M (EPS: -$0.16) in Q1 2024.

• Cash and equivalents at quarter-end were $12.4M, down from $20.1M at year-end 2024, not including $32M in new proceeds.

• Operating expenses rose 29% to $11.3M, mainly due to higher personnel, R&D, and regulatory costs.

Outlook and guidance

• Expense growth expected to remain below revenue growth for the full year, supporting operating leverage.

• Revenue guidance for 2025 remains $36M–$41M, with upside potential from expanded preclinical capacity and new product adoption.

• Management believes existing cash and equivalents are sufficient to support operations for at least the next twelve months.

• The company expects continued operating losses as it expands commercialization and R&D activities.

• Expect 15–20 new site activations in 2025; capital revenue to be smoother due to subscription model.